| Literature DB >> 31514733 |
Liyuan Wu1, Feiya Yang2, Liming Song3, Zejun Xiao1, Sujun Han1, Song Wu4, Sai Liu3, Qingbao He3, Nianzeng Xing5.
Abstract
PURPOSE: To compare the peri-operative outcomes of females undergoing laparoscopic intracorporeal urinary diversions (ICUD) and extracorporeal urinary diversions (ECUD) after laparoscopic radical cystectomies (LRC). PATIENTS AND METHODS: Thirty-eight females who underwent LRCs and urinary diversions from February 2008 to October 2018 were divided into two groups: the ECUD group (19 patients) and the ICUD group (19 patients). We retrospectively analysed the patients in terms of patients' demographics, peri-operative outcomes, and oncological follow-ups.Entities:
Keywords: Bladder cancer; Female; Laparoscopic radical cystectomy; Surgical technique
Mesh:
Year: 2019 PMID: 31514733 PMCID: PMC6743101 DOI: 10.1186/s12957-019-1678-5
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Patients demographics
| Variables | Extracorporeal | Intracorporeal |
|
|---|---|---|---|
| Patients, | 19 | 19 | |
| Age (mean ± SD), year | 62.5 ± 8.54 | 67.9 ± 11.40 | 0.173 |
| BMI (mean ± SD), kg/m2 | 25.5 ± 2.97 | 25.3 ± 2.74 | 0.867 |
| Charlson comorbidity index (median [range]) | 4 [2–9] | 3 [2–5] | 0.548 |
| ASA score, | > 0.9 | ||
| 1–2 | 17 (89%) | 17 (89%) | |
| 3 | 2 (11%) | 2 (11%) | |
| Neoadjuvant chemotherapy, n (%) | 4 (21%) | 3 (16%) | > 0.9 |
| Pre-eGFR (mean ± SD), mL/(min·1.73 m2) | 86.3 ± 28.87 | 85.9 ± 34.57 | 0.972 |
| Pre-Hb (mean ± SD), g/L | 116.9 ± 16.81 | 118.6 ± 13.94 | 0.765 |
| Preoperative diagnosis, | > 0.9 | ||
| NMIBC | 7 (37%) | 8 (42%) | |
| MIBC | 12 (63%) | 11 (58%) | |
| Clinical stage | 0.720 | ||
| Ta/T1/Tis | 7 (37%) | 8 (42%) | |
| T2 | 9 (47%) | 5 (26%) | |
| T3 | 3 (16%) | 5 (26%) | |
| T4 | 0 (0%) | 1 (5%) | |
| Clinical stage | 0.405 | ||
| N0 | 17 (89%) | 14 (74%) | |
| N1 | 2 (11%) | 5 (26%) |
BMI body mass index, ASA American Society of Anesthesiologists, Pre-eGFR pre-estimated glomerular filtration rate, MIBC muscle-invasive bladder cancer, NMIBC non-muscle-invasive bladder cancer
Surgical outcomes for female patients
| Variables | Extracorporeal ( | Intracorporeal ( |
|
|---|---|---|---|
| Diversion type, | 0.737 | ||
| Ileal conduit | 11 (58%) | 13 (68%) | |
| Neobladder | 8 (42%) | 6 (32%) | |
| Operative time (mean ± SD), min | 364.6 ± 72.30 | 297.1 ± 48.24 | 0.007 |
| EBL (mean ± SD), mL | 393.1 ± 387.46 | 267.0 ± 205.69 | 0.252 |
| Transfusion, | 7 (37%) | 1 (5%) | 0.042 |
| ICU stay after surgery, n (%) | 2 (10%) | 1 (5%) | > 0.9 |
| Time to flatus (median [range]), days | 5 [3–9] | 3 [1–6] | 0.020 |
| Time to intake of liquid diet (median [range]), days | 5 [4–8] | 4 [2–18] | 0.087 |
| Time to ambulation (median [range]), days | 2 [0–5] | 1 [1–3] | 0.022 |
| Time to remove Jackson-Pratt drain (median [range]), days | 14 [5–23] | 10 [4–30] | 0.549 |
| Length of hospital stay after surgery (median [range]), days | 22 [14–45] | 13 [7–22] | 0.002 |
| Final pathologic stage | 0.527 | ||
| Ta/T1/Tis | 10 (53%) | 9 (47%) | |
| T2 | 6 (32%) | 4 (21%) | |
| T3 | 2 (10%) | 5 (26%) | |
| T4 | 1 (5%) | 1 (5%) | |
| Pathologic stage | 0.631 | ||
| N0 | 13 (68%) | 13 (68%) | |
| N1 | 3 (16%) | 0 (0%) | |
| N2 | 3 (16%) | 3 (16%) | |
| N3 | 0 (0%) | 3 (16%) | |
| Lymph node yield (mean ± SD), | 12.9 ± 7.81 | 18.6 ± 11.51 | 0.140 |
| Lymph node positive patients, | 7 (37%) | 6 (32%) | > 0.9 |
| Positive surgical margin, | 2 (11%) | 4 (21%) | 0.660 |
EBL estimated blood loss
Surgical outcomes for ileal conduit
| Variables | Extracorporeal ( | Intracorporeal ( |
|
|---|---|---|---|
| Operative time (mean ± SD), min | 330.0 ± 53.67 | 288.5 ± 45.99 | 0.101 |
| EBL (mean ± SD), mL | 600.0 ± 485.80 | 242.7 ± 178.75 | 0.134 |
| Transfusion, | 5 (46%) | 1 (7.7%) | 0.048 |
| ICU stay after surgery, | 2 (18%) | 1 (8%) | 0.435 |
| Time to flatus (median [range]), days | 4 [3–7] | 3 [1–6] | 0.099 |
| Time to intake of liquid diet (median [range]), days | 5 [4–8] | 4 [2–18] | 0.169 |
| Time to ambulation (median [range]), days | 1 [0–2] | 1 [1–3] | 0.052 |
| Time to remove Jackson-Pratt drain (median [range]), days | 12 [7–17] | 8 [4–30] | 0.758 |
| Length of hospital stay after surgery (median [range]), days | 15 [14–23] | 14 [7–22] | 0.234 |
| Lymph node yield (mean ± SD), | 9.8 ± 10.15 | 20.2 ± 11.08 | 0.070 |
| Lymph node positive patients, | 5 (46%) | 5 (39%) | 0.527 |
| Positive surgical margin, | 2 (18%) | 3 (23%) | 0.585 |
Surgical outcomes for neobladder
| Variables | Extracorporeal ( | Intracorporeal ( |
|
|---|---|---|---|
| Operative time (mean ± SD), min | 394.3 ± 76.35 | 352.5 ± 10.61 | 0.486 |
| EBL (mean ± SD), mL | 230.0 ± 158.01 | 425.0 ± 388.91 | 0.606 |
| Transfusion, | 2 (25%) | 0 (0%) | 0.308 |
| ICU stay after surgery, | 0 (0%) | 0 (0%) | . |
| Time to flatus (median [range]), days | 5 [3–9] | 2 [3–5] | 0.361 |
| Time to intake of liquid diet (median [range]), days | 5 [4–6] | 4 [3–5] | 0.280 |
| Time to ambulation (median [range]), days | 2 [1–5] | 2 [2–3] | 0.190 |
| Time to remove Jackson-Pratt drain (median [range]), days | 16 [5–23] | 18 [8–28] | 0.769 |
| Length of hospital stay after surgery (median [range]), days | 23 [20–45] | 10 [7–15] | 0.039 |
| Lymph node yield (mean ± SD), | 15.4 ± 4.39 | 8.5 ± 12.02 | 0.562 |
| Lymph node positive patients, | 2 (25%) | 1 (17%) | 0.615 |
| Positive surgical margin, | 0 (0%) | 1 (17%) | 0.429 |
| Complete continence in the daytime, | 6 (75%) | 6 (100%) | 0.308 |
| Complete continence at night, | 6 (75%) | 3 (50%) | 0.343 |
Follow-up data
| Variables | Extracorporeal ( | Intracorporeal ( |
|
|---|---|---|---|
| Follow-up time (mean ± SD), months | 48.7 ± 30.58 | 26.4 ± 8.29 | 0.329 |
| Post- eGFR (mean ± SD), mL/(min·1.73 m2) | 79.0 ± 19.95 | 86.2 ± 34.7 | 0.516 |
| 30-day complication rates, | 0.227 | ||
| Minor (I–II) | 9 (47%) | 5 (32%) | 0.313 |
| Major (III–V) | 1 (5%) | 1 (5%) | > 0.9 |
| 90-day complication rates, | 0.142 | ||
| Minor (I–II) | 1 (5%) | 2 (11%) | > 0.9 |
| Major (III–V) | 0 (0%) | 2 (11%) | 0.486 |
| Metastasis, | 2 (11%) | 5 (26%) | 0.405 |
| Overall survival, | 16 (84%) | 17 (89%) | > 0.9 |
Post-eGFR post-estimated glomerular filtration rate
Complications classified by Clavien grade
| Clavien grade | 30 days | 90 days | ||||
|---|---|---|---|---|---|---|
| ECUD | ICUD |
| ECUD | ICUD |
| |
| 1 | 1 | 3 | 0.302 | 0 | 1 | > 0.9 |
| 2 | 8 | 2 | 0.026 | 1 | 1 | > 0.9 |
| 3 | 1 | 0 | > 0.9 | 0 | 1 | > 0.9 |
| 4 | 0 | 0 | 0 | 0 | ||
| 5 | 0 | 1 | > 0.9 | 0 | 1 | > 0.9 |
Complications by system
| ECUD | ICUD | |||
|---|---|---|---|---|
| 0–30 days | 30–90 days | 0–30 days | 30–90 days | |
| Haematological ( | ||||
| Hypoproteinemia | 8 | 1 | 0 | 0 |
| Great saphenous varicosity | 1 | 0 | 0 | 0 |
| Deep venous thrombosis | 0 | 0 | 1 | 0 |
| Infectious ( | ||||
| Wound infection | 0 | 0 | 1 | 0 |
| Pneumonia | 1 | 0 | 0 | 1 |
| Vaginitis | 0 | 0 | 2 | 0 |
| Gastrointestinal ( | ||||
| Ileus | 0 | 0 | 1 | 2 |
| Multiple organ failure ( | 0 | 0 | 1 | 0 |
| Pulmonary metastasis ( | 0 | 0 | 0 | 1 |
Fig. 1Kaplan-Meier survival estimates between the ECUD and ICUD groups. Log-rank test p = 0.862